A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer
| Autor: | Deborah Citrin, Ethan Bergvall, Paula M. Jacobs, Yolanda McKinney, Stephanie Harmon, James L. Gulley, Peter L. Choyke, Baris Turkbey, Sherif Mehralivand, Ravi A. Madan, Martin G. Pomper, Stephen Adler, Joanna H. Shih, M. Liza Lindenberg, Anna Couvillon, Esther Mena, Ronnie C. Mease |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
PET-CT
Lesion detection business.industry Concordance medicine.disease 030218 nuclear medicine & medical imaging Disease course Androgen deprivation therapy 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Sodium fluoride Medicine Radiology Nuclear Medicine and imaging business Nuclear medicine Prospective cohort study |
| Zdroj: | Journal of Nuclear Medicine. 59:1665-1671 |
| ISSN: | 2159-662X 0161-5505 |
| DOI: | 10.2967/jnumed.117.207373 |
| Popis: | The purpose of this study was to compare the diagnostic performance of 18F-DCFBC PET/CT, a first-generation 18F-labeled prostate-specific membrane antigen (PSMA)-targeted agent, and 18F-NaF PET/CT, a sensitive marker of osteoblastic activity, in a prospective cohort of patients with metastatic prostate cancer. Methods: Twenty-eight prostate cancer patients with metastatic disease on conventional imaging prospectively received up to 4 PET/CT scans. All patients completed baseline 18F-DCFBC PET/CT and 18F-NaF PET/CT scans, and 23 patients completed follow-up imaging, with a median follow-up interval of 5.7 mo (range, 4.2-12.6 mo). Lesion detection was compared across the 2 PET/CT agents at each time point. Detection and SUV characteristics of each PET/CT agent were compared with serum prostate-specific antigen (PSA) levels and treatment status at the time of baseline imaging using nonparametric statistical testing (Spearman correlation, Wilcoxon rank). Results: Twenty-six patients had metastatic disease detected on 18F-NaF or 18F-DCFBC at baseline, and 2 patients were negative on both scans. Three patients demonstrated soft tissue-only disease. Of 241 lesions detected at baseline, 56 were soft-tissue lesions identified by 18F-DCFBC only and 185 bone lesions detected on 18F-NaF or 18F-DCFBC. 18F-NaF detected significantly more bone lesions than 18F-DCFBC (P 0.5, P 0.1). When PSA levels were combined with treatment status, patients with below-median levels of PSA ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|